Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i2.20
36 pages

Targeted Delivery of Radiolabeled Imaging and Therapeutic Agents: Bifunctional Radiopharmaceuticals

Hideo Saji
Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan

ABSTRAKT

Clinical application of radioactive diagnostic and therapeutic agents constitutes one of the great advances in noninvasive medicine, nuclear medicine. The radioactive agents used in the nuclear medical field are called "radiopharmaceuticals," and are required to exhibit high and specific localization of radioactivity into target tissue. Among radionuclides used in radiopharmaceuticals, radiometals such as 99mTc and 111In have received much attention because of their nuclear physical characteristics and widespread availability. However, since these metallic elements are not constituents of bioactive molecules, they cannot simply replace common constituent atoms in biologically interesting compounds. Thus, demand for biospecific radiopharmaceuticals constitutes a great challenge in rational design of biologically active molecules labeled with metallic radionuclides, and evolves into a generation of bifunctional radiopharmaceuticals. Molecules contain both a biologically active site and a chelating group for binding the metallic radionuclide in which attachment of a chelating group does not affect the inherent biospecificity of the mother compound. This paper describes recent progress in research of macro- and small-molecular bifunctional radiopharmaceuticals for targeted diagnosis and therapy.


Articles with similar content:

Inorganic Nanoparticles for X-Ray Computed Tomography Imaging
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 5
Justine Wallyn, Mohamed F. Attia, Thierry F. Vandamme, Nicolas Anton
Niosomes as Nano-Delivery Systems in the Pharmaceutical Field
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 2
Cristal Cerqueira, Elisabete P. dos Santos, Claudia Regina E. Mansur
A New Horizon in Modifications of Chitosan: Syntheses and Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 2
Ashish Jain, Satish Shilpi, Ankit Jain, Pooja Hurkat, Arvind Gulbake, Sanjay Kumar Jain
Colloidal Drug Delivery Systems: Current Status and Future Directions
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 2
Goutam Rath, Tarun Garg, Amit Kumar Goyal
Role of Block Copolymer Nanoconstructs in Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 2
H. G. Agrawal, K. K. Upadhyay, C. Schatz, Sebastian Lecommandoux, J. F. Le Meins, Ambikanandan Misra, C. Upadhyay